Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen P Mulligan

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Leukemia & Lymphoma|October 6, 2007
Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab--double jeopardyStephen P Mulligan
Leukemia & Lymphoma|March 29, 2012
Monoclonal B-lymphocytosis: reflections and definitionsStephen P Mulligan
Blood|August 3, 2023
Karyotype and outcome in CLLStephen P Mulligan
Blood Advances|April 20, 2026
Hypertension and CLL: a common and hazardous relationshipStephen P Mulligan
Blood|December 26, 2024
An ALPINE guide to covalent BTKis in CLLStephen P Mulligan
Blood Advances|June 26, 2025
COVID-19 and CLL in Sweden: lessons learned?Stephen P Mulligan
Haematologica|April 2, 2015
Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemiaSuneet Sandhu, Stephen P Mulligan
Leukemia & Lymphoma|June 1, 2012
Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotypeO Giles Best, Stephen P Mulligan
Leukemia & Lymphoma|November 9, 2012
The phosphoinositide 3-kinase pathway in chronic lymphocytic leukemia: evidence for phosphatase and tensin homolog deletion on chromosome 10 deregulationO Giles Best, Stephen P Mulligan
Leukemia & Lymphoma|September 25, 2019
Chronic lymphocytic leukemia, skin and other second cancersStephen P Mulligan, Stephen Shumack, Alexander Guminski
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Leukemia & Lymphoma|October 6, 2007
Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab--double jeopardyStephen P Mulligan
Leukemia & Lymphoma|March 29, 2012
Monoclonal B-lymphocytosis: reflections and definitionsStephen P Mulligan
Blood|August 3, 2023
Karyotype and outcome in CLLStephen P Mulligan
Blood Advances|April 20, 2026
Hypertension and CLL: a common and hazardous relationshipStephen P Mulligan
Blood|December 26, 2024
An ALPINE guide to covalent BTKis in CLLStephen P Mulligan
Blood Advances|June 26, 2025
COVID-19 and CLL in Sweden: lessons learned?Stephen P Mulligan
Haematologica|April 2, 2015
Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemiaSuneet Sandhu, Stephen P Mulligan
Leukemia & Lymphoma|June 1, 2012
Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotypeO Giles Best, Stephen P Mulligan
Leukemia & Lymphoma|November 9, 2012
The phosphoinositide 3-kinase pathway in chronic lymphocytic leukemia: evidence for phosphatase and tensin homolog deletion on chromosome 10 deregulationO Giles Best, Stephen P Mulligan
Leukemia & Lymphoma|September 25, 2019
Chronic lymphocytic leukemia, skin and other second cancersStephen P Mulligan, Stephen Shumack, Alexander Guminski
Pageof 9